Research Article
Prognosis of Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis: Assessment according to GAP Stage
Table 3
Anticancer treatment-related complications, classified according to GAP stage and treatment modality.
| | | Total | GAP stage I | GAP stage II/III | p value |
| | Surgery (Total=6, GAP stage I=6, GAP stage II/III =0) | | AE-IPF | 1 (16.7) | 1 (16.7) | 0 | | | Pneumonia | 2 (33.3) | 2 (33.3) | 0 | | | Pneumothorax | 2 (33.3) | 2 (33.3) | 0 | | | Chylothorax | 1 (16.7) | 1 (16.7) | 0 | | | MV > 2 days | 1 (16.7) | 1 (16.7) | 0 | |
| | Chemotherapy (Total=30, GAP stage I=21, GAP stage II/III =9) | | AE-IPF | 9 (31.0) | 3 (14.3) | 6 (66.7) | 0.008 | | Pneumonia | 11 (36.7.0) | 7 (33.3) | 4 (44.4) | 0.687 | | Cytopenia | 17 (56.7) | 12 (57.1) | 5 (55.6) | 1.000 | | GI trouble | 13 (43.3) | 8 (38.1) | 5 (55.6) | 0.443 | | PTE | 4 (13.3) | 1 (4.8) | 3 (33.3) | 0.069 | | Neuropathy | 3 (10.3) | 2 (9.5) | 1 (11.1) | 1.000 |
| | Concurrent chemoradiotherapy (Total=21, GAP stage I=16, GAP stage II/III =5) | | AE-IPF | 6 (28.6) | 4 (25.0) | 2 (40.0) | 0.598 | | Pneumonia | 5 (22.7) | 1 (6.3) | 4 (80.0) | 0.004 | | Cytopenia | 15 (71.4) | 11 (68.8) | 4 (80.0) | 1.000 | | GI trouble | 5 (23.8) | 3 (18.8) | 2 (40.0) | 0.553 | | PTE | 1 (4.8) | 1 (6.3) | 0 (0.0) | 1.000 | | Pneumonitis | 8 (36.4) | 4 (25.0) | 4 (80.0) | 0.047 | | Esophagitis | 3 (14.3) | 2 (12.5) | 1 (20.0) | 1.000 |
|
|
Values are presented as No. (%).
Abbreviations: AE-IPF, acute exacerbation of idiopathic pulmonary fibrosis; GAP, gender, age, and physiology; GI, gastrointestinal; MV, mechanical ventilation; PTE, pulmonary thromboembolism.
|
